Perrigo Co. PLC isn’t making it easy for a bloc of board members to succeed in pushing to divest the firm’s Rx generic business. The company's finances are stabilizing despite challenges such as ongoing price erosion hammering the prescription generics sector.
The company's Aug. 10 earnings briefing was led by CEO John Hendrickson, who announced plans in June to step down...